APA (7th ed.) Citation

Hewitt, D. B., Nissen, N., Hatoum, H., Musher, B., Seng, J., Coveler, A. L., . . . Lavu, H. (2022). A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer. Annals of surgery, 275(1), 45. https://doi.org/10.1097/SLA.0000000000004669

Chicago Style (17th ed.) Citation

Hewitt, Daniel Brock, et al. "A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer." Annals of Surgery 275, no. 1 (2022): 45. https://doi.org/10.1097/SLA.0000000000004669.

MLA (9th ed.) Citation

Hewitt, Daniel Brock, et al. "A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer." Annals of Surgery, vol. 275, no. 1, 2022, p. 45, https://doi.org/10.1097/SLA.0000000000004669.